NumFin

Catalyst Pharmaceuticals, Inc.

Sümbol: CPRX

NASDAQ

14.72

USD

Turuhind täna

  • 21.9975

    P/E suhe

  • -0.6049

    PEG suhe

  • 1.73B

    MRK Cap

  • 0.00%

    DIV tootlus

Catalyst Pharmaceuticals, Inc. (CPRX) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Catalyst Pharmaceuticals, Inc. (CPRX) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 44.346 M, mis on 8.922 % gowth. Kogu perioodi keskmine brutokasum on 36.5 M, mis on 7.635 %. Keskmine brutokasumi suhtarv on 0.281 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.140 %, mis on võrdne -0.218 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Catalyst Pharmaceuticals, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.252. Käibevara valdkonnas on CPRX aruandlusvaluutas 219.329. Märkimisväärne osa neist varadest, täpsemalt 137.636, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.539%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 16.489, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 3.188 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.181%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 387.881 aruandlusvaluutas. Selle aspekti aastane muutus on 0.291%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 53.514, varude hind on 15.64 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 194.05.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042002

balance-sheet.row.cash-and-short-term-investments

585.64137.6298.4191.3
140.3
94.5
53.5
84
40.4
58.4
39.3
23.7
15.4
6
5.5
7.8
11.8
15.9
20.4
0.8
0.2
0.1

balance-sheet.row.short-term-investments

00019.8
10
5
36.9
26.5
26.5
30.2
30.2
21.5
14
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

177.7653.510.46.6
6
10.5
0
0
0
0
0
0
0
0
0.1
0
0
0.1
0.1
0
0
0

balance-sheet.row.inventory

45.7615.66.87.9
4.7
2
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

20.1812.55.24.4
8.3
4.4
1.6
1.2
1
1.5
0
0
1.3
0.2
0.2
0.1
0.1
0.5
0.1
0
0
0

balance-sheet.row.total-current-assets

851.23219.3320.8210.1
159.2
111.4
55.2
85.2
41.5
59.9
43.8
25.3
16.7
6.2
5.8
7.9
11.9
16.5
20.6
0.8
0.2
0.1

balance-sheet.row.property-plant-equipment-net

15.33.73.64
0.1
1
0.2
0.2
0.2
0.2
0.1
0
0.1
0
0
0.1
0.1
0.1
0
0
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

720.8419432.50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

720.8419432.50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

396.916.500
0
0
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

119.538.318.723.7
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

-367.51000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-non-current-assets

885.02252.654.827.7
33.1
1
5.3
0.2
0.3
0.2
0.1
0
0.1
0
0.1
0.1
0.1
0.1
0
0
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1

balance-sheet.row.total-assets

1736.24471.9375.6237.8
192.4
112.4
60.4
85.4
41.7
60.1
43.9
25.4
16.8
6.2
5.8
8
12
16.7
20.6
0.8
0.2
0.1

balance-sheet.row.account-payables

27.214.842.8
4.3
4.1
2.3
1.9
0.9
1.8
1.8
0.9
1.4
0.3
0.1
0.2
0.3
0.2
0.4
0.1
0
0

balance-sheet.row.short-term-debt

1.430.40.30.3
0
0.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

24.140.78.70.1
0
1.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

13.313.23.63.9
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

00-1.30
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

1.79---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

113.9760.253.30.2
0.1
0.2
7.2
2.3
1.2
1.6
4
1.3
0.3
0.6
0.2
0
1.1
0.1
0.3
0.3
0
0

balance-sheet.row.total-non-current-liabilities

47.78817.63.9
0
0.6
0.2
0.2
0.3
1.2
2.8
1.8
0.5
1.7
0
0.1
0
0.1
0
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1

balance-sheet.row.capital-lease-obligations

14.033.23.63.9
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

290.868475.231
22.8
24.7
9.7
4.4
2.4
4.6
8.7
4
2.2
2.5
0.3
0.3
1.5
0.4
0.8
0.3
0.1
0.1

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.430.10.10.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0.1
0
0

balance-sheet.row.retained-earnings

404.32121.349.9-26.3
-53.7
-128.7
-160.6
-126.6
-108.1
-90.1
-69.8
-54.3
-42.2
-38.1
-31.7
-27.7
-20.5
-9.9
-5.8
-3
-1.2
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

0.0600-0.1
0
0
0
-0.2
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1040.58266.5250.4233.2
223.2
216.2
211.3
207.6
147.5
145.5
105.1
75.8
56.8
41.9
37.3
35.4
31.1
26.2
25.6
3.4
1.3
0

balance-sheet.row.total-stockholders-equity

1445.38387.9300.4206.8
169.6
87.6
50.8
81
39.3
55.5
35.2
21.4
14.6
3.8
5.5
7.6
10.6
16.3
19.8
0.4
0.1
0

balance-sheet.row.total-liabilities-and-stockholders-equity

1736.24471.9375.6237.8
192.4
112.4
60.4
85.4
41.7
60.1
43.9
25.4
16.8
6.2
5.8
8
12
16.7
20.6
0.8
0.2
0.1

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

1445.38387.9300.4206.8
169.6
87.6
50.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

1736.24---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

396.916.5019.8
10
5
41.9
26.5
26.5
30.2
30.2
21.5
14
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

14.43.63.93.9
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

-571.24-134.1-294.5-167.6
-130.2
-88.9
-16.6
-57.5
-13.9
-28.2
-9.1
-2.2
-1.4
-6
-5.5
-7.8
-11.8
-15.9
-20.4
-0.8
-0.2
-0.1

Rahavoogude aruanne

Catalyst Pharmaceuticals, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.236 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 2.79, mis tähistab 1.905 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 10.82 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -293502000.000. See on -32.871 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 33.14, -81.51, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -13.65, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

71.4171.483.139.5
75
31.9
-34
-18.4
-18.1
-20.2
-15.5
-12.2
-4.1
-6.4
-4
-7.2
-10.6
-4.1
-2.7
-1.8
-0.5

cash-flows.row.depreciation-and-amortization

32.8833.11.20.2
0.9
0.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.deferred-income-tax

-17.82-17.84.99.3
-33
0
0
0
0
-1.7
0
-0.2
-1.5
0
-0.5
-0.6
-0.7
-0.6
-1.2
0
0

cash-flows.row.stock-based-compensation

14.2514.37.96.1
6.3
3.8
3.6
2.4
1.8
1.6
0.8
0.2
0.3
0.4
0.5
0.6
0.7
0.6
1.2
0
0

cash-flows.row.change-in-working-capital

-37.32-37.313.75
-4.1
-1.1
4.7
2
-0.9
0.7
0.8
0.2
-0.3
0.6
-0.2
-1.1
1.6
-0.9
0.3
0.2
0

cash-flows.row.account-receivables

-43.08-43.1-3.8-0.6
4.5
-10.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-4.74-4.71.1-3.2
-2.7
-1.9
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

10.8210.81.2-1.5
0.1
1.8
0.4
1
-0.9
0
1
-0.5
1.1
0.2
-0.1
-0.1
0.1
-0.2
0.4
0
0

cash-flows.row.other-working-capital

25.34-0.315.310.4
-6.1
9.6
4.4
1
0
0.7
-0.2
0.7
-1.4
0.5
-0.1
-1
1.4
-0.6
-0.1
0
0

cash-flows.row.other-non-cash-items

80.279.95.20.3
0
-0.3
0
0.2
-0.9
1.6
1
2.1
0.3
0.3
0.5
0.6
0.7
0.6
1.2
1.2
0.3

cash-flows.row.net-cash-provided-by-operating-activities

143.6000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-115.52-198.50-1
0
0
-0.1
0
-0.1
0
-0.1
0
-0.1
0
0
0
0
-0.1
0
0
0

cash-flows.row.acquisitions-net

00100
5
-37.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-13.46-13.5-10-10
-10
-34.7
-36.8
0
-0.1
0
-8.7
-7.5
-14
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0019.20
5
72
21.4
0
3.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-243.81-81.5-100
-5
37.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-293.5-293.59.2-11
-5
37.2
-15.5
0
3.6
0
-8.7
-7.5
-14.1
0
0
0
0
-0.1
0
0
0

cash-flows.row.debt-repayment

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

2.792.84.14.1
0.8
1.1
0
53.8
34.9
34.9
26.7
14.1
9.6
5.5
1.5
3.7
4.1
0
20.9
1
0

cash-flows.row.common-stock-repurchased

00-6.9-12.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-13.65-13.64.5-0.2
0
1.1
0.3
3.6
-34.8
2.3
1.8
4.1
5
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-10.86-10.91.7-8.1
0.7
1.1
0.3
57.4
0.1
37.2
28.6
18.2
14.6
5.5
1.5
3.7
4.1
0
20.9
1
0

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-160.76-160.812741.2
40.7
73
-40.9
43.6
-14.3
19.1
6.9
0.8
-4.6
0.6
-2.3
-4
-4.2
-4.5
19.7
0.6
-0.2

cash-flows.row.cash-at-end-of-period

585.64137.6298.4171.4
130.2
89.5
16.6
57.5
13.9
28.2
9.1
2.2
1.4
6
5.5
7.8
11.8
15.9
20.4
0.8
0.2

cash-flows.row.cash-at-beginning-of-period

746.4298.4171.4130.2
89.5
16.6
57.5
13.9
28.2
9.1
2.2
1.4
6
5.5
7.8
11.8
15.9
20.4
0.8
0.2
0.4

cash-flows.row.operating-cash-flow

143.6143.611660.4
45
34.6
-25.7
-13.7
-18
-18
-12.9
-9.9
-5.1
-5
-3.8
-7.7
-8.3
-4.4
-1.2
-0.5
-0.2

cash-flows.row.capital-expenditure

-115.52-198.50-1
0
0
-0.1
0
-0.1
0
-0.1
0
-0.1
0
0
0
0
-0.1
0
0
0

cash-flows.row.free-cash-flow

28.08-54.911659.4
45
34.6
-25.8
-13.7
-18.1
-18
-13
-9.9
-5.2
-5
-3.8
-7.7
-8.3
-4.5
-1.2
-0.5
-0.2

Kasumiaruande rida

Catalyst Pharmaceuticals, Inc. tulud muutusid võrreldes eelmise perioodiga 0.859%. CPRX brutokasum on teatatud 313.67. Ettevõtte tegevuskulud on 226.86, mille muutus võrreldes eelmise aastaga on 190.951%. Kulud amortisatsioonikulud on 33.14, mis on 25.750% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 226.86, mis näitab 190.951% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.148% kasvu võrreldes eelmise aastaga. Tegevustulu on 86.81, mis näitab -0.148% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.140%. Eelmise aasta puhaskasum oli 71.41.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002

income-statement-row.row.total-revenue

398.2398.2214.2140.8
119.1
102.3
0.5
0
0
0
0
0
0
0
0.5
0
0
0
0
0
0
0
0

income-statement-row.row.cost-of-revenue

61.0384.534.421.9
17
14.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

337.18313.7179.8118.9
102
87.5
0.5
0
0
0
0
0
0
0
0.5
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

93.15---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

47.02---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

86.69---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

12.537.72.90.3
0.6
1.6
1.3
0.5
0.3
0.1
0.1
0
0
0
0
0
0
0
0
0
0
-0.4
0.1

income-statement-row.row.operating-expenses

250.37226.97866.6
60.7
55.7
35.8
18.7
19.3
20.4
14.6
10.3
5.2
6.1
4.5
7.3
10.9
5
2.9
1.8
0.5
-0.4
0.3

income-statement-row.row.cost-and-expenses

311.39311.4112.488.4
77.8
70.5
35.8
18.7
19.3
20.4
14.6
10.3
5.2
6.1
4.5
7.3
10.9
5
2.9
1.8
0.5
-0.4
0.3

income-statement-row.row.interest-income

003.60.3
0.6
1.6
1.3
0.5
0.3
0.1
0.1
0
0
0
0
0
0.3
0
0
0
0
0
0

income-statement-row.row.interest-expense

00-4.10
0
0
1.3
0.5
0.3
0.1
0.1
0
0
0
0
0
0.3
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

86.69---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

7.77.72.90.3
0.6
1.6
1.3
0.3
1.2
0.2
-0.9
-1.9
1.1
-0.3
0
0
0.3
0.9
0.2
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

12.537.72.90.3
0.6
1.6
1.3
0.5
0.3
0.1
0.1
0
0
0
0
0
0
0
0
0
0
-0.4
0.1

income-statement-row.row.total-operating-expenses

7.77.72.90.3
0.6
1.6
1.3
0.3
1.2
0.2
-0.9
-1.9
1.1
-0.3
0
0
0.3
0.9
0.2
0
0
0
0

income-statement-row.row.interest-expense

00-4.10
0
0
1.3
0.5
0.3
0.1
0.1
0
0
0
0
0
0.3
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

32.8133.11.20.2
0.9
0.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.ebitda-caps

119.62---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

86.8186.8101.852.4
41.3
31.8
-35.3
-18.7
-19.3
-20.4
-14.6
-10.3
-5.2
-6.1
-4
-7.3
-10.9
-5
-2.9
-1.8
-0.5
-0.4
-0.3

income-statement-row.row.income-before-tax

94.5194.5104.752.7
41.9
33.4
-34
-18.4
-18.1
-20.2
-15.5
-12.2
-4.1
-6.4
-4
-7.2
-10.6
-4.1
-2.7
-1.8
-0.5
0
-0.3

income-statement-row.row.income-tax-expense

23.123.121.613.2
-33.1
1.5
2.6
0.1
-0.9
-0.1
1
1.8
-1.2
0.3
0
0
0
0
0
0
0
0.4
0

income-statement-row.row.net-income

71.4171.483.139.5
75
31.9
-34
-18.4
-18.1
-20.2
-15.5
-12.2
-4.1
-6.4
-4
-7.2
-10.6
-4.1
-2.7
-1.8
-0.5
-0.4
-0.3
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Catalyst Pharmaceuticals, Inc. (CPRX) koguvara?

Catalyst Pharmaceuticals, Inc. (CPRX) koguvara on 471907000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 213256000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.847.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 0.263.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.179.

Mis on ettevõtte kogutulu?

Kogutulu on 0.218.

Mis on Catalyst Pharmaceuticals, Inc. (CPRX) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 71410000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 3557000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 226860000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 137636000.000.